NCT01704274View on ClinicalTrials.gov

GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

December 31, 2019

Conditions
Prostate Cancer
Interventions
OTHER

Low Dose GTN 0.0285 mg/hr

Low Dose GTN

OTHER

High Dose GTN 0.057 mg/hr

High Dose GTN

OTHER

Placebo

Placebo

Trial Locations (1)

K7L 2V7

Centre for Applied Urological Research/Kingston General Hospital, Kingston

All Listed Sponsors
lead

Dr. D. Robert Siemens

OTHER

NCT01704274 - GTN Therapy on Biomarkers of Immune Escape in Men With Biochemical Recurrence of Prostate Cancer After Primary Therapy | Biotech Hunter | Biotech Hunter